$HIMS

HIMSHims & Hers Health, Inc. Class A Common Stock

YouTube 频道最近怎么谈 Hims & Hers Health(HIMS)?

过去 24 小时(截至 11-18),1 个 YouTube 频道谈到 Hims & Hers Health(HIMS),共 1 条。最近一条:Schwab Network,2026-11-18。

本窗口内的全部观点与内容

截至 11-18
11-18
Schwab Network发布 2026-11-18
《Wednesday's Final Takeaways: Gold at 52-Week Lows, Housing Market Mixed》
$HIMS中性
AI 摘要 · HIMS 推出 Peptides Plus,包含五种联合疗法,有望在肽类需求上升之际吸引传统远程医疗之外的新客户并带来经常性收入;但首批疗法均未获 FDA 批准,HIMS 表示安全性、有效性和剂量仍不确定,监管与科学风险可能实质性威胁其增长计划。

Hims&Hers 可能错过了“多肽热潮之夏”,但随着它推出新的“Peptides Plus”平台,提供五种组合疗法,针对从精力与恢复到细胞健康的各种需求,一个“多肽热潮之冬”可能即将到来。

Hims&Hers may have missed out on the " hot peptide summer," but there may be a " hot peptide winter" coming, as it launches its new "Peptides Plus" platform offering five combination therapies targeting everything from energy and recovery to cellular health.

这一举措出台之际,多肽的需求正在上升,但这里存在一个重大障碍。最初的治疗方案均未获得美国食品药品监督管理局(FDA)的批准,公司自己也承认,关于其安全性、有效性和合适剂量,仍有很多需要了解。

This move comes at a time when demand for peptides is increasing, but there is a major obstacle here . None of the initial treatments are approved by the Food and Drug Administration (FDA), and the company itself acknowledges that there is still much to learn about their safety, effectiveness, and appropriate dosages .

已显示 1 / 本页 1 条
看这只股票的全部记录